Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.737
+0.017 (2.32%)
Nov 21, 2024, 11:47 AM EST - Market open
Cosmos Health Revenue
Cosmos Health had revenue of $12.41M in the quarter ending September 30, 2024, a decrease of -3.22%. This brings the company's revenue in the last twelve months to $56.04M, up 13.01% year-over-year. In the year 2023, Cosmos Health had annual revenue of $53.38M with 6.02% growth.
Revenue (ttm)
$56.04M
Revenue Growth
+13.01%
P/S Ratio
0.22
Revenue / Employee
$455,627
Employees
123
Market Cap
13.07M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
Dec 31, 2019 | 39.68M | 2.59M | 6.99% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Trinity Biotech | 59.13M |
STRATA Skin Sciences | 32.68M |
Streamline Health Solutions | 20.30M |
Psychemedics | 20.26M |
Vivos Therapeutics | 14.58M |
Ensysce Biosciences | 4.42M |
Traws Pharma | 226.00K |
AIM ImmunoTech | 190.00K |
COSM News
- 3 days ago - Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets - Accesswire
- 6 days ago - Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M - Accesswire
- 8 days ago - Cosmos Health Issues Letter to Shareholders - Accesswire
- 20 days ago - Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21% - Accesswire
- 2 months ago - Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands - Accesswire
- 2 months ago - Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins - Accesswire
- 2 months ago - Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits - Accesswire
- 2 months ago - Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion - Accesswire